 | • レポートコード：D005-00190 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、化学療法誘発性好中球減少症（CIN）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。化学療法誘発性好中球減少症（CIN）治療の種類別市場規模（抗生物質療法、コロニー刺激因子療法、顆粒球輸血、脾臓摘出術、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Amgen、Biogenomics Limited、Baxter International、Sanofi、Dr. Reddy’s Laboratory、Novartis AG、Apotex、Teva Pharmaceuticals Industries、Ligand Pharmaceuticals ・地域別グローバル市場分析 2015年-2020年 ・化学療法誘発性好中球減少症（CIN）治療の北米市場（アメリカ、カナダ、メキシコ） ・化学療法誘発性好中球減少症（CIN）治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・化学療法誘発性好中球減少症（CIN）治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・化学療法誘発性好中球減少症（CIN）治療の南米市場（ブラジル、アルゼンチン） ・化学療法誘発性好中球減少症（CIN）治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：抗生物質療法、コロニー刺激因子療法、顆粒球輸血、脾臓摘出術、その他 ・用途別分析：病院薬局、小売薬局、オンライン薬局 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Chemotherapy-Induced Neutropenia (CIN) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Chemotherapy-Induced Neutropenia (CIN) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Chemotherapy-Induced Neutropenia (CIN) Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Chemotherapy-Induced Neutropenia (CIN) Treatment market has been segmented into:
Antibiotic Therapy
Colony-Stimulating Factor Therapy
Granulocyte Transfusion
Splenectomy Procedure
Others
By Application, Chemotherapy-Induced Neutropenia (CIN) Treatment has been segmented into:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Chemotherapy-Induced Neutropenia (CIN) Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Chemotherapy-Induced Neutropenia (CIN) Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Chemotherapy-Induced Neutropenia (CIN) Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Chemotherapy-Induced Neutropenia (CIN) Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Chemotherapy-Induced Neutropenia (CIN) Treatment Market Share Analysis
Chemotherapy-Induced Neutropenia (CIN) Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Chemotherapy-Induced Neutropenia (CIN) Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Chemotherapy-Induced Neutropenia (CIN) Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Chemotherapy-Induced Neutropenia (CIN) Treatment are:
Amgen
Biogenomics Limited
Baxter International
Sanofi
Dr. Reddy’s Laboratory
Novartis AG
Apotex
Teva Pharmaceuticals Industries
Ligand Pharmaceuticals
Table of Contents
1 Chemotherapy-Induced Neutropenia (CIN) Treatment Market Overview
1.1 Product Overview and Scope of Chemotherapy-Induced Neutropenia (CIN) Treatment
1.2 Classification of Chemotherapy-Induced Neutropenia (CIN) Treatment by Type
1.2.1 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Type in 2019
1.2.3 Antibiotic Therapy
1.2.4 Colony-Stimulating Factor Therapy
1.2.5 Granulocyte Transfusion
1.2.6 Splenectomy Procedure
1.2.7 Others
1.3 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market by Application
1.3.1 Overview: Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market by Regions
1.4.1 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Chemotherapy-Induced Neutropenia (CIN) Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Chemotherapy-Induced Neutropenia (CIN) Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Chemotherapy-Induced Neutropenia (CIN) Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chemotherapy-Induced Neutropenia (CIN) Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Chemotherapy-Induced Neutropenia (CIN) Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chemotherapy-Induced Neutropenia (CIN) Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Amgen SWOT Analysis
2.1.4 Amgen Product and Services
2.1.5 Amgen Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Biogenomics Limited
2.2.1 Biogenomics Limited Details
2.2.2 Biogenomics Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Biogenomics Limited SWOT Analysis
2.2.4 Biogenomics Limited Product and Services
2.2.5 Biogenomics Limited Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Baxter International
2.3.1 Baxter International Details
2.3.2 Baxter International Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Baxter International SWOT Analysis
2.3.4 Baxter International Product and Services
2.3.5 Baxter International Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Sanofi SWOT Analysis
2.4.4 Sanofi Product and Services
2.4.5 Sanofi Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Dr. Reddy’s Laboratory
2.5.1 Dr. Reddy’s Laboratory Details
2.5.2 Dr. Reddy’s Laboratory Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Dr. Reddy’s Laboratory SWOT Analysis
2.5.4 Dr. Reddy’s Laboratory Product and Services
2.5.5 Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis AG SWOT Analysis
2.6.4 Novartis AG Product and Services
2.6.5 Novartis AG Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Apotex
2.7.1 Apotex Details
2.7.2 Apotex Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Apotex SWOT Analysis
2.7.4 Apotex Product and Services
2.7.5 Apotex Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Teva Pharmaceuticals Industries
2.8.1 Teva Pharmaceuticals Industries Details
2.8.2 Teva Pharmaceuticals Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Teva Pharmaceuticals Industries SWOT Analysis
2.8.4 Teva Pharmaceuticals Industries Product and Services
2.8.5 Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Ligand Pharmaceuticals
2.9.1 Ligand Pharmaceuticals Details
2.9.2 Ligand Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Ligand Pharmaceuticals SWOT Analysis
2.9.4 Ligand Pharmaceuticals Product and Services
2.9.5 Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Chemotherapy-Induced Neutropenia (CIN) Treatment Players Market Share
3.2.2 Top 10 Chemotherapy-Induced Neutropenia (CIN) Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Market Share by Regions
4.2 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
5 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries
5.1 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries (2015-2020)
5.2 USA Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
6 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries
6.1 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries (2015-2020)
6.2 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
6.4 France Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries
7.1 Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries (2015-2020)
7.2 China Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
7.5 India Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
8 South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries
8.1 South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries (2015-2020)
8.2 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Chemotherapy-Induced Neutropenia (CIN) Treatment by Countries
9.1 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Forecast by Type (2019-2024)
10.3 Antibiotic Therapy Revenue Growth Rate (2015-2025)
10.4 Colony-Stimulating Factor Therapy Revenue Growth Rate (2015-2025)
10.5 Granulocyte Transfusion Revenue Growth Rate (2015-2025)
10.6 Splenectomy Procedure Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Segment by Application
11.1 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Application (2015-2020)
11.2 Chemotherapy-Induced Neutropenia (CIN) Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacy Revenue Growth (2015-2020)
11.4 Retail Pharmacy Revenue Growth (2015-2020)
11.5 Online Pharmacy Revenue Growth (2015-2020)
12 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Size Forecast (2021-2025)
12.1 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Size Forecast (2021-2025)
12.2 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Forecast by Regions (2021-2025)
12.3 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
12.6 South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Chemotherapy-Induced Neutropenia (CIN) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Amgen Corporate Information, Location and Competitors
Table 6. Amgen Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 7. Amgen Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Amgen SWOT Analysis
Table 9. Amgen Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 10. Amgen Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Biogenomics Limited Corporate Information, Location and Competitors
Table 12. Biogenomics Limited Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 13. Biogenomics Limited Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Biogenomics Limited SWOT Analysis
Table 15. Biogenomics Limited Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 16. Biogenomics Limited Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Baxter International Corporate Information, Location and Competitors
Table 18. Baxter International Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 19. Baxter International Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Baxter International SWOT Analysis
Table 21. Baxter International Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 22. Baxter International Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Sanofi Corporate Information, Location and Competitors
Table 24. Sanofi Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 25. Sanofi Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Sanofi SWOT Analysis
Table 27. Sanofi Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 28. Sanofi Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Dr. Reddy’s Laboratory Corporate Information, Location and Competitors
Table 30. Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 31. Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Dr. Reddy’s Laboratory SWOT Analysis
Table 33. Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 34. Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Novartis AG Corporate Information, Location and Competitors
Table 36. Novartis AG Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 37. Novartis AG Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Novartis AG SWOT Analysis
Table 39. Novartis AG Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 40. Novartis AG Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Apotex Corporate Information, Location and Competitors
Table 42. Apotex Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 43. Apotex Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 44. Apotex SWOT Analysis
Table 45. Apotex Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 46. Apotex Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Teva Pharmaceuticals Industries Corporate Information, Location and Competitors
Table 48. Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 49. Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 50. Teva Pharmaceuticals Industries SWOT Analysis
Table 51. Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 52. Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Ligand Pharmaceuticals Corporate Information, Location and Competitors
Table 54. Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia (CIN) Treatment Major Business
Table 55. Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia (CIN) Treatment Total Revenue (USD Million) (2017-2018)
Table 56. Ligand Pharmaceuticals SWOT Analysis
Table 57. Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia (CIN) Treatment Product and Solutions
Table 58. Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) by Players (2015-2020)
Table 60. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Players (2015-2020)
Table 61. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) by Regions (2015-2020)
Table 62. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Regions (2015-2020)
Table 63. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries (2015-2020)
Table 64. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Table 65. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 66. Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 67. South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Countries (2015-2020)
Table 68. South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Table 69. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 70. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Table 71. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) by Type (2015-2020)
Table 72. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Type (2015-2020)
Table 73. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Forecast by Type (2021-2025)
Table 74. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue by Application (2015-2020)
Table 75. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Application (2015-2020)
Table 76. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Forecast by Application (2021-2025)
Table 77. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Chemotherapy-Induced Neutropenia (CIN) Treatment Picture
Figure 2. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Type in 2019
Figure 3. Antibiotic Therapy Picture
Figure 4. Colony-Stimulating Factor Therapy Picture
Figure 5. Granulocyte Transfusion Picture
Figure 6. Splenectomy Procedure Picture
Figure 7. Others Picture
Figure 8. Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Application in 2019
Figure 9. Hospital Pharmacy Picture
Figure 10. Retail Pharmacy Picture
Figure 11. Online Pharmacy Picture
Figure 12. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share in 2019
Figure 21. Global Top 10 Players Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Regions (2015-2020)
Figure 25. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Regions in 2018
Figure 26. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 29. South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 31. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Figure 32. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries in 2019
Figure 33. USA Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries in 2019
Figure 38. Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 39. UK Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 40. France Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Russia Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries in 2019
Figure 45. China Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 48. India Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 50. South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries in 2019
Figure 52. Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 57. UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Type (2015-2020)
Figure 61. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Type in 2019
Figure 62. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Share Forecast by Type (2021-2025)
Figure 63. Global Antibiotic Therapy Revenue Growth Rate (2015-2020)
Figure 64. Global Colony-Stimulating Factor Therapy Revenue Growth Rate (2015-2020)
Figure 65. Global Granulocyte Transfusion Revenue Growth Rate (2015-2020)
Figure 66. Global Splenectomy Procedure Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Application (2015-2020)
Figure 69. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Share by Application in 2019
Figure 70. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospital Pharmacy Revenue Growth Rate (2015-2020)
Figure 72. Global Retail Pharmacy Revenue Growth Rate (2015-2020)
Figure 73. Global Online Pharmacy Revenue Growth Rate (2015-2020)
Figure 74. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
Figure 78. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
Figure 80. South America Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
化学療法誘発悪心＆嘔吐（CINV）用薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global ChemOtherapy Induced Nausea and Vomiting （CINV） Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2…- 好中球減少症治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Neutropenia Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Neutropenia Drugs market re…
- 人工多能性幹細胞の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Induced Pluripotent Stem Cells market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 11.7% in the forecast period of 2020 to 2025 and will expected to reach USD 130.7 million by 2025, from USD 84 million in 2019. The Induced P…
- 変態誘発塑性鋼の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Transformation Induced Plasticity Steel market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Trans…
- 化学療法用椅子の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Chemotherapy Chairs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.2% in the forecast period of 2020 to 2025 and will expected to reach USD 511.8 million by 2025, from USD 451.2 million in 2019. The Chemotherapy Chair…